We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+7.83%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.71B
AUM Growth
-$70.8M
Cap. Flow
-$26.8M
Cap. Flow %
-1.56%
Top 10 Hldgs %
65.15%
Holding
70
New
6
Increased
13
Reduced
5
Closed
21

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$30.3M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$24.8M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$23.4M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$22.7M
5
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$21.8M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$41.4M
2
DSGN icon
Design Therapeutics
DSGN
+$32.4M
3
ETNB
89bio
ETNB
+$25.6M
4
AXSM icon
Axsome Therapeutics
AXSM
+$24.4M
5
VRDN icon
Viridian Therapeutics
VRDN
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.77%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
26
Enliven Therapeutics
ELVN
$4.43B
$16.6M 0.97%
1,216,712
-719,421
-37% -$12.1M
PRAX icon
27
Praxis Precision Medicines
PRAX
$10.1B
$16.2M 0.95%
633,333
– –
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.56B
$16.2M 0.94%
600,000
– –
INSM icon
29
Insmed
INSM
$28.6B
$14.5M 0.85%
+575,000
New +$13.2M
ZNTL icon
30
Zentalis Pharmaceuticals
ZNTL
$300M
$14M 0.82%
700,000
-395,000
-36% -$10M
AXNX
31
DELISTED
Axonics, Inc. Common Stock
AXNX
$14M 0.82%
250,000
-72,240
-22% -$4.06M
LBPH
32
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$13.1M 0.76%
2,353,141
– –
RNAM
33
DELISTED
Avidity Biosciences
RNAM
$11.2M 0.66%
1,762,115
-850,000
-33% -$7.32M
IRON icon
34
Disc Medicine
IRON
$2.97B
$10.6M 0.62%
225,000
– –
COGT icon
35
Cogent Biosciences
COGT
$7.24B
$9.75M 0.57%
1,000,000
– –
RCKT icon
36
Rocket Pharmaceuticals
RCKT
$394M
$9.22M 0.54%
450,000
-418,550
-48% -$7.61M
GHRS icon
37
GH Research
GHRS
$2.08B
$5.96M 0.35%
593,043
– –
RAPT
38
DELISTED
RAPT Therapeutics
RAPT
$5.4M 0.32%
40,625
– –
VERV
39
DELISTED
Verve Therapeutics
VERV
$4.64M 0.27%
350,000
– –
STOK icon
40
Stoke Therapeutics
STOK
$2.11B
$4.29M 0.25%
1,087,807
– –
CNTA
41
DELISTED
Centessa Pharmaceuticals
CNTA
$3.63M 0.21%
561,600
– –
VIGL
42
DELISTED
Vigil Neuroscience
VIGL
$3.32M 0.19%
616,786
– –
ALXO icon
43
ALX Oncology
ALXO
$283M
$2.94M 0.17%
612,079
– –
BHVN icon
44
Biohaven
BHVN
$2.21B
$2.13M 0.12%
81,963
– –
BCAB icon
45
BioAtla
BCAB
$5.74M
$2.01M 0.12%
23,622
– –
NMRA icon
46
Neumora Therapeutics
NMRA
$302M
$1.3M 0.08%
+92,293
New +$1.15M
AUTL
47
Autolus Therapeutics
AUTL
$562M
$914K 0.05%
392,167
– –
HARP
48
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$218K 0.01%
54,060
– –
ORTX
49
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$198K 0.01%
25,664
– –
AKRO
50
DELISTED
Akero Therapeutics
AKRO
– –
-115,000
Closed -$5.37M
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2023 Portfolio in Review

As of Q3 2023, Cormorant Asset Management held 70 positions worth $1.71B, down 4% from $1.79B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Cormorant Asset Management's Q3 2023 filing shows 6 new, 13 increased, 5 reduced and 21 closed positions. Its largest new stake was RayzeBio, Inc. Common Stock: 1,182,263 shares worth $26.2M. The largest sale was Protagonist Therapeutics, an estimated $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Cormorant Asset Management's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 1,182,263 shares worth $26.2M.
  • Cormorant Asset Management added most to Apellis Pharmaceuticals in Q3 2023, an estimated $30.3M increase.
  • Cormorant Asset Management's biggest Q3 2023 reduction was Enliven Therapeutics, cutting an estimated $12.1M.
  • Cormorant Asset Management fully exited Protagonist Therapeutics in Q3 2023, selling an estimated $41.4M.
  • Cormorant Asset Management's ten largest holdings make up 65% of its $1.71B portfolio in Q3 2023.
  • Cormorant Asset Management opened 6 new positions and closed 21 in Q3 2023.
  • Cormorant Asset Management's portfolio value fell 4% quarter-over-quarter to $1.71B.

Based on Cormorant Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.